Overview

An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED

Status:
Recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Phase:

Phase 2

Details

Lead Sponsor:

Pharmicell Co., Ltd.